Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000

Key Points The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing. The insider retains 253,083 shares. 10 stocks we like better than Grail › Chief Financial Officer Aaron Freidin reported a sale of 7,900 shares of Grail (NASDAQ:GRAL) on Aug. 27, 2026, according to a recent SEC Form 4 filing . Transaction summary Metric Value Transaction value $672,000 Shares sold 7,900 Post-transaction shares (directly held) 253,083 Post-transaction value $20.9 million Transaction value based on SEC Form 4 weighted average sale price ($85.01); post-transaction value based on Aug. 27, 2026, market close ($82.50). Key questions What were the execution details for this transaction? The shares were sold in multiple transactions at prices ranging from $85 to $85.11, resulting in a weighted average price of $85.01 per share. The sale occurred on a day when the stock finished the session at a market close of $82.50. What was the composition of the equity involved in the sale? The 7,900 shares of common stock included 314 shares that Freidin previously acquired through the company employee stock purchase plan on May 14, 2026. What is the scale of the CFO's remaining equity position? Following this transaction, the CFO continues to hold approximately 253,000 shares directly, representing a 0.5% ownership interest in the company and valued at roughly $20.2 million as of the Aug. 28, 2026, market close. How does the company's financial profile align with its current operations? The healthcare company, which provides multi-cancer early detection testing services, generated $165.3 million in revenue over the trailing twelve months while recording a net loss of $391.6 million. Company Overview Metric Value Share Price (as of market close 2026-08-28) $80.00 Market Capitalization $3.5 billion Revenue (TTM) $165.3 million Net Income (TTM) -$391.6 million Company Snapshot Grail develops and commercializes multi-cancer early detection testing services, with its flagship Galleri product designed for asymptomatic individuals over 50 years of age, as well as diagnostic aids to accelerate cancer diagnosis for patients with clinical suspicion of malignancy. The company generates revenue through direct provision of cancer screening and diagnostic testing services, as well as through development services, including support for ongoing clinical studies, pilot testing, and research programs. Grail targets asymptomatic individuals aged 50 and above seeking proactive cancer screening, as well as healthcare providers and patients requiring accelerated diagnostic resolution for suspected malignancies. Grail is a commercial-stage healthcare diagnostics company with a market capitalization of $3.5 billion, operating with 910 employees from its Menlo Park headquarters. The company is focused on advancing early cancer detection through proprietary testing methodologies, positioning itself at the intersection of preventive oncology and precision diagnostics. Despite current operating losses, Grail's significant TTM revenue base of $165.3 million and substantial market valuation reflect investor confidence in its long-term potential in the high-growth cancer diagnostics market. What this transaction means for investors Insider selling can sometimes trigger shareholder concern, as it may reflect turmoil within the company. But given the context of this sale, this doesn't appear to be anything that should cause shareholders to worry. To start, Freidin sold 7,900 shares on Aug. 27 but still retained 253,083 shares after the sale. That level of holdings shows alignment with the company's continued success. Additionally, there's also the stock price performance to consider. Over the last year, the Grail stock price has climbed 106.9%. In comparison, over the same period, the S&P 500 is up 18.1%. That lends even more credence to the idea that this is likely a routine sale, as the insider may just be taking some profits off the table after the stock price has had such a huge run-up. For what's next, however, analysts suggest some restraint in expectations may be warranted. Of the nine analysts who cover the company, the median one-year price target is $74.50, according to CNN. From the price as of this writing, $79.10, that would represent a 5.8% loss. Should you buy stock in Grail right now? Before you buy stock in Grail, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Grail wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997 !* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876 !* Now, it’s worth noting Stock Advisor’s total average return is 978 % — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of September 8, 2026. Jack Delaney has no position in any of the stocks mentioned. The Motley Fool recommends Grail. The Motley Fool has a disclosure policy .

The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing.

Chief Financial Officer Aaron Freidin reported a sale of 7,900 shares of Grail (NASDAQ:GRAL) on Aug. 27, 2026, according to a recent SEC Form 4 filing .

Transaction value based on SEC Form 4 weighted average sale price ($85.01); post-transaction value based on Aug. 27, 2026, market close ($82.50).

Grail is a commercial-stage healthcare diagnostics company with a market capitalization of $3.5 billion, operating with 910 employees from its Menlo Park headquarters. The company is focused on advancing early cancer detection through proprietary testing methodologies, positioning itself at the intersection of preventive oncology and precision diagnostics. Despite current operating losses, Grail's significant TTM revenue base of $165.3 million and substantial market valuation reflect investor confidence in its long-term potential in the high-growth cancer diagnostics market.

Insider selling can sometimes trigger shareholder concern, as it may reflect turmoil within the company. But given the context of this sale, this doesn't appear to be anything that should cause shareholders to worry. To start, Freidin sold 7,900 shares on Aug. 27 but still retained 253,083 shares after the sale. That level of holdings shows alignment with the company's continued success.

Additionally, there's also the stock price performance to consider. Over the last year, the Grail stock price has climbed 106.9%. In comparison, over the same period, the S&P 500 is up 18.1%. That lends even more credence to the idea that this is likely a routine sale, as the insider may just be taking some profits off the table after the stock price has had such a huge run-up.

For what's next, however, analysts suggest some restraint in expectations may be warranted. Of the nine analysts who cover the company, the median one-year price target is $74.50, according to CNN. From the price as of this writing, $79.10, that would represent a 5.8% loss.